The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Iterum Therapeutics plc | SHS | G6333L101 | 346 | 1,733,170 | SH | SOLE | 1,733,170 | 0 | 0 | ||
IDEAYA Biosciences Inc | COM | 45166A102 | 36,718 | 2,660,713 | SH | SOLE | 2,660,713 | 0 | 0 | ||
Berkshire Grey Inc | COM CL A | 084656107 | 20,739 | 14,302,523 | SH | SOLE | 14,302,523 | 0 | 0 | ||
Astra Space Inc | COM CL A | 04634X103 | 0 | 0 | SH | SOLE | 0 | 0 | 0 |